PMID- 29956727
OWN - NLM
STAT- MEDLINE
DCOM- 20181126
LR  - 20220410
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 53
IP  - 3
DP  - 2018 Sep
TI  - Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via 
      CIP2A/PP2A/ERK signaling in prostate cancer.
PG  - 1279-1288
LID - 10.3892/ijo.2018.4464 [doi]
AB  - Polyphyllin I (PPI) is a natural compound extracted from the rhizomes of Paris 
      polyphylla and has been used to treat fevers and headaches in China. In the 
      present study, the antitumor activity of PPI in prostate cancer (PC) cells was 
      evaluated. At low doses, PPI decreased proliferation, invasion and 
      epithelial-mesenchymal transition (EMT) in PC cells. PPI decreased the expression 
      of matrix metalloproteinase 7 (MMP7), an enzyme that is critical for tumor 
      metastasis. PPI also decreased the expression of Snail and vimentin, which are 
      EMT-associated factors. Additionally, PPI suppressed AP-1 transcriptional 
      activity and AP-1 binding to the MMP7 and vimentin promoters. The results 
      demonstrated that PPI downregulated the phosphorylation of extracellular 
      signaling‑related kinase (ERK), which is upstream modulator of AP-1. The results 
      of the present study demonstrated that PPI may inhibit the cancerous inhibitor of 
      protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A)/ERK axis, 
      downregulate the expression of MMP7, vimentin, and Snail, and suppress tumor 
      invasion and EMT. A PC xenograft mouse model was employed and the results 
      revealed that PPI may decrease tumor growth and weight. Additionally, PPI may 
      inhibit proliferating cell nuclear antigen expression and CIP2A/PP2A/ERK 
      signaling pathway in PPI-treated tumors. Therefore, the results of the present 
      study suggest that PPI may suppress the growth, invasion and EMT of PC cells via 
      inhibition of CIP2A/PP2A/ERK signaling axis. As a result, PPI may be a novel 
      target for the treatment of PC.
FAU - Liu, Xuewen
AU  - Liu X
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Sun, Zhiting
AU  - Sun Z
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Deng, Jikun
AU  - Deng J
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Liu, Jun
AU  - Liu J
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Ma, Kaihuai
AU  - Ma K
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Si, Yuan
AU  - Si Y
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Zhang, Te
AU  - Zhang T
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Feng, Tingting
AU  - Feng T
AD  - School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, 
      P.R. China.
FAU - Liu, Ying
AU  - Liu Y
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
FAU - Tan, Yan
AU  - Tan Y
AD  - School of Basic Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180629
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Autoantigens)
RN  - 0 (CIP2A protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (polyphyllin I)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.1.3.16 (Protein Phosphatase 2)
RN  - K49P2K8WLX (Diosgenin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Autoantigens/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Diosgenin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Down-Regulation
MH  - Drug Evaluation, Preclinical
MH  - Epithelial-Mesenchymal Transition/*drug effects
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins
MH  - Male
MH  - Melanthiaceae/chemistry
MH  - Membrane Proteins/metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Invasiveness/prevention & control
MH  - Phosphorylation/drug effects
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Protein Phosphatase 2/metabolism
MH  - Signal Transduction/*drug effects
MH  - Xenograft Model Antitumor Assays
EDAT- 2018/06/30 06:00
MHDA- 2018/11/27 06:00
CRDT- 2018/06/30 06:00
PHST- 2018/01/19 00:00 [received]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/11/27 06:00 [medline]
PHST- 2018/06/30 06:00 [entrez]
AID - 10.3892/ijo.2018.4464 [doi]
PST - ppublish
SO  - Int J Oncol. 2018 Sep;53(3):1279-1288. doi: 10.3892/ijo.2018.4464. Epub 2018 Jun 
      29.